Pifithrin-μ (PFT-μ) is a synthetic compound that belongs to the group of p53 inhibitors. The chemical name of Pifithrin-mu is 2-phenylethynesulfonamide. The molecular formula is C8H7NO2S, and the formula weight is 181.21 g/mol. The CAS number of this compound is 64984-31-2.
Top Ten Keywords from Google:
- Pifithrin-μ mechanism of action
- Pifithrin-μ uses
- Pifithrin-μ apoptosis
- Pifithrin-μ sigma
- Pifithrin-μ cancer
- Pifithrin-μ cas
- Pifithrin-μ mw
- Pifithrin-μ p53
Synonyms for Pifithrin-μ:
- Pifithrin mu
Health Benefits of Pifithrin-μ:
Pifithrin-μ has been shown to have a variety of potential health benefits, including its ability to inhibit p53-dependent apoptosis. In cells, the p53 protein helps regulate cell growth and division while preventing cells with DNA damage from continuing to replicate.
Pifithrin-μ has also been shown to have potential antitumor effects, inhibiting the growth of certain types of cancer cells. It has been used as a potential promising therapeutic agent for cancer therapy.
Potential effects of Pifithrin-μ: Pifithrin-μ is a potent inhibitor of p53-dependent apoptosis in cells. It can inhibit the activity of this protein to prevent cells from self-destructing when they reach a certain level of DNA damage. This mechanism of action can be beneficial in certain conditions, such as cancer. It protects the cells and leads to irrepairable DNA damage.
Pifithrin-μ inhibits the transcriptional activity of p53 by binding to its DNA-binding domain. It acts as a chaperone antagonist, stabilizing the conformation of the protein, which prevents it from binding to DNA and activating its gene targets. By inhibiting p53 activity, Pifithrin-μ can protect cells from undergoing apoptosis even when DNA damage occurs within them.
The use of Pifithrin-μ as a therapeutic agent has not been approved by the FDA yet. Its use only falls under the research phase. The potential side effects of Pifithrin-μ are not well known, and it should only be used under the guidance of a healthcare professional.
The side effects of Pifithrin-μ in humans are not yet known as it is not approved by the FDA for use.
The therapeutic dose of Pifithrin-μ has not been established in humans since it is not approved for use. The dose ranges for research purposes only, and the administration mode is intravenous or intraperitoneal injection.
Pifithrin-μ is a compound with potential anti-cancer effects by inhibiting the p53 protein. However, its potential side effects are not well-known, and it is not approved for use as a therapeutic agent in humans due to its trial and experimental phase. A healthcare professional should only use it for research purposes